Global Alzheimer's Platform Foundation

What Global Alzheimer's Platform Foundation does

Global Alzheimer's Platform Foundation (GAP) is a Washington, D.C.-headquartered nonprofit founded in 2014 (firmographics indicates 2013) to reduce the time, cost, and risk of Alzheimer's and Parkinson's disease clinical trials. It operates GAP-Net, a network of over 100 private and academic clinical research sites across North America and Europe, and runs the Bio-Hermes platform studies — observational, multi-modality studies comparing blood-based biomarkers, digital cognitive and speech tests, retinal imaging, and PET/MRI against each other across diverse populations. Bio-Hermes-001 enrolled over 1,000 participants in 18 months across 17 US sites and demonstrated strong correlation between blood tests (particularly p-tau 217) and amyloid plaques, with 24% of participants from underrepresented communities. Bio-Hermes-002 is an ongoing international study across 25 sites in the US, UK, and Canada.

The core technology is a biomarker comparison platform rather than a single product: GAP coordinates 25+ blood-based biomarkers, 15+ digital tests (including speech analytics, computerized cognitive assessments, and digital remote brain health screenings), and four cognitive assessment modalities, with data hosted on the AD Workbench cloud platform managed by Gates Ventures' Alzheimer's Disease Data Initiative. Supporting programs include GAP Participant Services (GPS) with dedicated Liaisons and Community Connectors, the Inclusive Research Initiative to promote trial diversity, the Acti-V8 Your Brain awareness program, and the Citizen Scientist Awards. A separate Biospecimen Inquiries service extends GAP's reach by offering diverse, high-quality samples from understudied communities to external researchers.

GAP does not sell products or services commercially. Revenue is generated through a nonprofit funding model comprising grants (including from the Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator), donations, and strategic co-development partnerships with pharmaceutical companies (Biogen, Eli Lilly, Roche, Sanofi, AbbVie, Merck), diagnostic and technology firms (C2N Diagnostics, Quanterix, Retispec, Aural Analytics, Cognivue, SomaLogic, Linus Health, Siemens Healthineers, Alamar Biosciences, Circular Genomics, IXICO), and research institutions (LifeArc, UK Dementia Research Institute). Distribution is direct to enterprise counterparties through the GAP-Net site network and partner collaborations, with an annual conference as a community-building channel.

Name

Global Alzheimer's Platform Foundation

Legal name

Global Alzheimer's Platform Foundation

Website

https://globalalzplatform.org

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Global Alzheimer's Platform Foundation is a nonprofit operating GAP-Net, a network of 100+ clinical research sites, and conducting the Bio-Hermes biomarker platform studies to accelerate Alzheimer's and Parkinson's disease clinical trials through pharma, diagnostic, and technology partnerships.

Ownership category

akta.pro rank

Product category

Alzheimer's Clinical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Alzheimer's clinical research
• Biomarker platform studies
• Clinical trial site network
• Neurodegenerative disease trials
• Clinical trial recruitment

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Foundation/Nonprofit Funding: GAP operates as a nonprofit organization funded through grants, donations, and strategic partnerships with pharmaceutical and diagnostic companies. The foundation does not generate revenue through product sales but through collaborations where partners contribute to biomarker research studies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Global Alzheimer's Platform Foundation (GAP) is a nonprofit foundation that runs observational biomarker platform studies (Bio-Hermes-001 and Bio-Hermes-002) comparing blood-based, digital, speech, retinal, and PET imaging biomarkers for Alzheimer's and Parkinson's disease. These studies are enabled by the GAP-Net global network of more than 100 clinical research sites across North America and Europe, with supporting participant services (GPS), diversity programs (IRI), brain-health outreach, and biospecimen access for research partners.

Product overview

The Global Alzheimer's Platform Foundation operates as a nonprofit research organization offering a platform of clinical trial support programs rather than a commercial product. The core offerings include the Bio-Hermes and Bio-Hermes-002 biomarker studies (observational platform studies comparing blood-based and digital biomarkers for Alzheimer's diagnosis), supported by the GAP-Net network of 100+ clinical research sites worldwide. The platform is complemented by participant support services including GAP Participant Services (GPS) with GPS Liaisons and Community Connectors, the Inclusive Research Initiative for diversity promotion, Acti-V8 Your Brain brain health program, and the Citizen Scientist Awards. Additional services include biospecimen access and the Apheleia program.

Differentiator

Problem solved

Functional benefit

Brands

• GAP-Net: GAP's global network of clinical research sites across North America and Europe.
• Bio-Hermes
• GAP Participant Services (GPS)
• Inclusive Research Initiative (IRI)
• Acti-V8 Your Brain
• Apheleia

Products and services

• Bio-Hermes-001 Study First-ever blood and digital biomarker platform study comparing results of blood-based biomarker tests, digital cognitive tests, retinal exams, and speech analytics with brain amyloid PET scans across over 1,000 community-based participants (24% from underrepresented communities). For pharmaceutical, diagnostic, and technology research partners.
• Bio-Hermes-002 Study Observational platform study evaluating blood-based and digital biomarkers alongside MRI and PET imaging to improve prediction, detection, and diagnosis of Alzheimer's disease and related dementias across diverse populations in the US, UK, Canada, and beyond. For pharmaceutical, diagnostic, and technology research partners.
• GAP-Net Clinical Research Site Network Global network of over 100 private and academic clinical research sites across North America and Europe that connect neurodegenerative trials to researchers and participants, providing study start-up support and recruitment resources.
• GAP Participant Services (GPS) Flagship participant support service providing GPS Liaisons and Community Connectors offering high-touch support and resources to bridge clinical trial sites, community-based organizations, studies, and volunteers.
• Inclusive Research Initiative (IRI) Program promoting diversity in clinical research through community outreach and engagement to ensure underrepresented communities are represented in Alzheimer's and Parkinson's disease trials.
• Biospecimen Inquiries Service offering high-quality, unique biosamples with comprehensive participant data from understudied communities to research partners for Alzheimer's and related disease research.

Quantifiable outcome

• 24% diversity rate in Bio-Hermes-001 vs. typical <6% in Alzheimer's clinical trials
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

23 partnerships are on record, tiered core.

• Circular GenomicscoreStrategic or Co-development Partner · 28 May 2026Collaboration with Circular Genomics to analyze samples from the Bio-Hermes-001 study, leveraging Circular Genomics' circular RNA biomarker platform to advance Alzheimer's disease diagnosis, prognosis, and treatment.
• SanoficoreStrategic or Co-development Partner · 18 May 2026Sanofi joined as a new partner in the Bio-Hermes-002 study, an observational platform evaluating blood-based and digital biomarkers for improving prediction, detection, and diagnosis of Alzheimer's disease and related dementias. Sanofi will analyze additional biomarkers to augment the study's existing database.
• Siemens HealthineerscoreStrategic or Co-development Partner · 9 April 2026Strategic collaboration with Siemens Healthineers for the Bio-Hermes-002 study to enhance early diagnosis and monitoring of Alzheimer's disease through blood-based and digital biomarkers.
• LifeArccoreStrategic or Co-development Partner · 21 January 2026LifeArc partnered with GAP and UK Dementia Research Institute for the Bio-Hermes-002 study testing a finger-prick blood test for Alzheimer's diagnosis. LifeArc leads the international clinical trial involving 1,000 volunteers across UK, USA, and Canada.
• UK Dementia Research InstitutecoreStrategic or Co-development Partner · 21 January 2026UK Dementia Research Institute partnered with GAP and LifeArc for the Bio-Hermes-002 study, contributing to international research testing finger-prick blood tests for Alzheimer's diagnosis.
• Alamar BiosciencescoreStrategic or Co-development Partner · 9 January 2026Alamar Biosciences joined the Bio-Hermes studies, gaining access to biospecimens and data from both Bio-Hermes-001 and Bio-Hermes-002 studies, contributing its proprietary NULISA™ proteomics technology to the research platform.
• Clinical Neurology Specialists (CNS)coreStrategic or Co-development Partner · 6 January 2026Clinical Neurology Specialists (CNS) joined the GAP-sponsored Bio-Hermes-002 study as the only Las Vegas research site participating, expanding Alzheimer's research opportunities in the Las Vegas-area community.
• BiogencoreStrategic or Co-development PartnerExisting partner in Bio-Hermes-002 study providing biomarker assessments.
• Eli Lilly and CompanycoreStrategic or Co-development PartnerExisting partner in Bio-Hermes-002 study providing biomarker assessments and full genomic sequencing of study volunteers.
• RochecoreStrategic or Co-development PartnerExisting partner in Bio-Hermes-002 study providing biomarker assessments.
• IXICOcoreTechnology or IntegrationExisting partner in Bio-Hermes studies providing digital biomarker assessments.
• Gates Ventures Alzheimer's Disease Data InitiativecoreStrategic or Co-development PartnerManages the AD Workbench platform for hosting study data from Bio-Hermes studies, providing global secure cloud-based data sharing environment.
• Alzheimer's Drug Discovery Foundation (ADDF)coreStrategic or Co-development PartnerProvided funding for Bio-Hermes through its Diagnostics Accelerator (DxA) research initiative.
• AbbViecoreStrategic or Co-development PartnerPartner in Bio-Hermes study contributing to biomarker research.
• C2N DiagnosticscoreTechnology or IntegrationPartner providing blood biomarker tests (PrecivityAD) in Bio-Hermes studies.
• QuanterixcoreTechnology or IntegrationPartner providing ultra-sensitive biomarker detection technology in Bio-Hermes studies.
• RetispeccoreTechnology or IntegrationPartner providing retinal imaging biomarker technology in Bio-Hermes studies.
• Aural AnalyticscoreTechnology or IntegrationPartner providing speech analytics digital biomarker technology in Bio-Hermes studies.
• CognivuecoreTechnology or IntegrationPartner providing computerized cognitive assessment technology in Bio-Hermes studies.
• SomaLogiccoreTechnology or IntegrationPartner providing proteomics technology in Bio-Hermes studies.
• Linus HealthcoreTechnology or IntegrationPartner providing digital health assessments in Bio-Hermes studies.
• MerckcoreStrategic or Co-development PartnerPartner in Bio-Hermes study contributing to biomarker research.
• GAP-Net Clinical Research SitescoreStrategic or Co-development PartnerOver 100 clinical research sites across North America and Europe that are part of the GAP network (GAP-Net), conducting Alzheimer's and Parkinson's disease trials.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Alzheimer's Drug Discovery Foundation (ADDF): Nonprofit foundation that funds Alzheimer's diagnostics and drug discovery, including the Diagnostics Accelerator that funds GAP's Bio-Hermes. Directly comparable as a disease-specific research nonprofit targeting the same Alzheimer's pipeline.
• Cleveland Clinic Lou Ruvo Center for Brain Health: Alzheimer's and neurodegenerative clinical research center running industry-sponsored trials and biomarker studies. Comparable as an Alzheimer's-focused clinical-trial delivery organization with overlap to GAP's site-network mission.
• Banner Alzheimer's Institute: Nonprofit Alzheimer's research and clinical-trial organization running its own large-scale prevention and biomarker studies (e.g., API/Genentech partnership). Closely comparable as a translational research nonprofit running Alzheimer's clinical trials.
• BrightFocus Foundation: Nonprofit that provides research grants for Alzheimer's, macular degeneration, and glaucoma. Comparable as a disease-specific research funding nonprofit with overlapping Alzheimer's grant programs.
• UsAgainstAlzheimer's: Patient-advocacy and policy nonprofit focused on Alzheimer's treatment acceleration. Comparable as a nonprofit stakeholder in the Alzheimer's drug-development ecosystem with overlapping industry-collaboration and awareness missions.

Emerging players

• C2N Diagnostics: Developer of PrecivityAD, a blood-based Alzheimer's diagnostic assay that is itself being validated inside the Bio-Hermes studies. Comparable as an Alzheimer's blood-biomarker diagnostics company intersecting with GAP's research platform.
• Quanterix: Ultra-sensitive biomarker detection technology provider whose assays are used in Bio-Hermes. Comparable as a neurodegenerative biomarker technology vendor that both participates in and benefits from GAP-led validation studies.

Broad incumbents

• Biogen: Major Alzheimer's drug developer (aducanumab, lecanemab) that is also a Bio-Hermes-002 partner. Comparable as a broad incumbent industry player that both funds and competes for attention within GAP's research platform.
• National Institute on Aging (NIA): Federal agency that funds the majority of U.S. Alzheimer's and dementia research, including biomarker and clinical-trial infrastructure. Comparable as a dominant incumbent funder of the same Alzheimer's research ecosystem GAP operates in.
• Eli Lilly: Major Alzheimer's drug developer (donanemab) and Bio-Hermes-002 partner providing biomarker assessments and full genomic sequencing. Comparable as a leading commercial Alzheimer's player investing in GAP-led biomarker research.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/GAP_Foundation
• YouTubeyoutube.com/channel/UCAFdURPZNVdWZvNahpqKsDQ/videos
• Facebookfacebook.com/GlobalALZPlatform
• LinkedInlinkedin.com/company/global-alzheimer's-platform-foundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Alzheimer's Platform Foundation